Quaternary ammonium compounds
    171.
    发明授权
    Quaternary ammonium compounds 有权
    季铵化合物

    公开(公告)号:US06759406B1

    公开(公告)日:2004-07-06

    申请号:US10019804

    申请日:2002-03-25

    IPC分类号: C07D40906

    摘要: Compounds of formula corresponding to either formula (Ia) or (Ib): wherein: M represents a molecule that can be used for the treatment or diagnosis of pathologies caused by attack on the cartilage, R1, R2 and R3 represent an alkyl group, or R1, R2 and R3, together with the nitrogen atom carrying them, form a heterocycle, X represents a (C1-C6)alkylene chain in which one or more —CH2— groups are optionally replaced by a sulphur atom, an oxygen atom, or an —NR—, —CO—, —CO—NH—, —CO2—, —SO— or —SO2— group, n represents 0 or 1, Hal represents a halogen atom, or, R4 represents an alkyl group, Hal represents a halogen atom, represents a molecule that can be used for the treatment or diagnosis of pathologies caused by attack on the cartilage, wherein the nitrogen atom may optionally be included in a saturated or unsaturated nitrogen-containing heterocyclic system, or included in a double bond; and pharmaceutical compositions thereof.

    摘要翻译: 对应于式(Ia)或(Ib)的式的化合物:其中:M表示可用于治疗或诊断由软骨侵袭引起的病理学的分子,R1,R2和R3表示烷基,或 R1,R2和R3与携带它们的氮原子一起形成杂环,X表示(C1-C6)亚烷基链,其中一个或多个-CH 2 - 基团任选被硫原子,氧原子或 -NR - , - CO - , - CO - NH - , - CO 2 - , - SO-或-SO 2 - 基,n表示0或1,Hal表示卤素原子,或者,R4表示烷基,Hal表示 卤素原子表示可用于治疗或诊断由软骨侵袭引起的病理学的分子,其中氮原子可任选地包括在饱和或不饱和的含氮杂环体系中,或包括在双键中 ; 及其药物组合物。

    1-aza-2-alky-6-aryl-cycloalkanes
    176.
    发明授权
    1-aza-2-alky-6-aryl-cycloalkanes 失效
    1-氮杂-2-烷基-6-芳基 - 环烷烃

    公开(公告)号:US06451789B1

    公开(公告)日:2002-09-17

    申请号:US09964085

    申请日:2001-09-26

    IPC分类号: A61K3155

    摘要: Compound of formula (I): wherein: n represents 0 or 1, R1 represents hydrogen, arylalkyl, alkyl, acyl, alkoxycarbonyl, arylalkoxycarbonyl or trifluoroacetyl, R2 represents alkyl, X represents oxygen, chlorine, OR3, SR4 or NOR5, R3 represents hydrogen , alkyl, acyl, alkoxycarbonyl or arylalkoxycarbonyl, R4 represents hydrogen, alkyl or aryl, R5 represents hydrogen or optionally substituted alkyl, represents a single or double bond, Ar represents aryl or heteroaryl, its isomers and addition salts thereof with a pharmaceutically acceptable acid, and medicinal products containing the same which are useful as facilitators of memory and cognition and antalgic agents.

    摘要翻译: 式(I)化合物:其中:n表示0或1,R1表示氢,芳基烷基,烷基,酰基,烷氧基羰基,芳基烷氧基羰基或三氟乙酰基,R2表示烷基,X表示氧,氯,OR3,SR4或NOR5,R3表示氢 烷基,酰基,烷氧基羰基或芳基烷氧基羰基,R4代表氢,烷基或芳基,R5代表氢或任选取代的烷基,CUSTOM-CHARACTER FILE =“US06451789-20020917-P00900.TIF”ALT =“custom character”HE =“20 “WI =”20“ID =”CUSTOM-CHARACTER-00001“/>表示单键或双键,Ar表示芳基或杂芳基,其异构体和其药学上可接受的酸的加成盐,以及含有它们的药物 有用作记忆和认知和安踏药剂的促进者。

    Apparatus for regulating the flow rate of at least one fluid in simulated moving bed separation units
    177.
    发明授权
    Apparatus for regulating the flow rate of at least one fluid in simulated moving bed separation units 有权
    用于调节模拟移动床分离单元中的至少一种流体的流速的装置

    公开(公告)号:US06332982B1

    公开(公告)日:2001-12-25

    申请号:US09525454

    申请日:2000-03-15

    IPC分类号: B01D1508

    摘要: An apparatus and process for regulating the flow rate of at least one fluid or effluent circulating in a simulated moving bed comprises a plurality of beds disposed in a closed loop in at least one chromatographic column (1) and comprising at least one means for recirculating fluid and comprising at least two lines for injecting fluid at a controlled flow rate and at least two lines for withdrawing fluid, one of said withdrawal (extract or raffinate) lines being under flow rate control, the other (60) being under pressure control via at least one control valve (6), and is characterized in that said pressure controlled withdrawal line (60) comprises, in addition to the control valve, comprises at least one restriction means (201) enabling the pressure downstream of at least one of the beds to be reduced. One embodiment of the use of the invention is for separating a xylene isomer.

    摘要翻译: 用于调节在模拟移动床中循环的至少一种流体或流出物的流速的装置和方法包括在至少一个色谱柱(1)中设置在闭环中的多个床,并且包括至少一个用于再循环流体的装置 并且包括用于以受控流速喷射流体的至少两条线和用于抽出流体的至少两条线,所述抽出(提取物或提余液)管线之一处于流量控制之下,另一条管线(60)在压力控制下通过 至少一个控制阀(6),其特征在于,所述压力控制抽出管线(60)除了所述控制阀之外还包括至少一个限制装置(201),所述至少一个限制装置能使所述床中的至少一个床 要减少 本发明使用的一个实施方案是分离二甲苯异构体。

    9-(3,5-dimethoxyphenyl)-5,8,8a,9-tetrahydrofuro-[3′,4′:6,7]naphtho[2,3-d][1,3]dioxol-6(5aH)-one compounds
    179.
    发明授权
    9-(3,5-dimethoxyphenyl)-5,8,8a,9-tetrahydrofuro-[3′,4′:6,7]naphtho[2,3-d][1,3]dioxol-6(5aH)-one compounds 失效
    9-(3,5-二甲氧基苯基)-5,8,8a,9-四氢呋喃(3',4':6,7)萘并(2,3-d)(1,3)二氧杂环戊烯-6(5aH) 一种化合物

    公开(公告)号:US06281198B1

    公开(公告)日:2001-08-28

    申请号:US09697248

    申请日:2000-10-26

    IPC分类号: A61K31365

    CPC分类号: C07D493/04 Y02P20/55

    摘要: Compound of formula (I): wherein: R represents: a group of formula (i):  wherein X, Y and W are as defined in the description, or a group of formula (ii): —A—G  (ii) wherein: A represents a single bond or an optionally substituted alkylene chain, G represents a group selected from hydrogen, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, —OR2, —O—T1—NR3R4, —O—T1—NR2—T′1—NR3R4, —NR3R4, —NR2—T1—NR3R4, —NR2—T1—OR5, —NR2—T1—CO2R6, —NR2—T1—C(O)R6, —C(O)—NR3R4, —C(O)—NR2—T2, —O—C(O)T2, —O—C(S)—T2, —NR2—C(O)—T2, —NR2—C(S)—T2, —O—C(O)—O—T2, —O—C(O)—NR2—T2, —O—C(S)—O—T2, —O—C(S)—NR2—T2, —NR2—C(O)—O—T2, —NR2—C(O)—NR—T2, —NR2—C(S)—O—T2, —NR2—C(S)—NR6—T2 and —NR2—SO2—T3,  wherein R2, R3, R4, R5, R6, T1, T′1, T2 and T3 are as defined in the description, R1 represents a group selected from hydrogen, alkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, alkylcarbonyl, arylcarbonyl, arylalkylcarbonyl, heterocycloalkylcarbonyl, alkylsulphonyl, arylsulphonyl, arylalkylsulphonyl, phosphono, aryloxycarbonyl, alkoxycarbonyl and arylalkoxycarbonyl, its isomers, and also addition salts thereof with a pharmaceutically acceptable acid or base. Medicinal products containing the same which are useful in the treatment of cancer.

    摘要翻译: 式(I)的化合物:其中:R表示:式(ⅰ)的基团:其中X,Y和W如说明书中所定义,或式(ⅱ)的基团:其中:A表示单键或 任选取代的亚烷基链,G表示选自氢,环烷基,杂环烷基,芳基,杂芳基,-OR2,-O-T1-NR3R4,-O-T1-NR2-T'1-NR3R4,-NR3R4,-NR2 -T 1 -NR 3 R 4,-NR 2 -T 1 -OR 5,-NR 2 -T 1 -CO 2 R 6,-NR 2 -T 1 -C(O)R 6,-C(O)-NR 3 R 4,-C(O)-NR 2 -T 2,-OC (O)T 2,-OC(S)-T 2,-NR 2 -C(O)-T 2,-NR 2 -C(S)-T 2,-OC(O)-O-T 2,-OC(O) -T 2,-OC(S)-O-T2,-OC(S)-NR2-T2,-NR2-C(O)-O-T2,-NR2-C(O)-NR-T2, C(S)-O-T2,-NR2-C(S)-NR6-T2和-NR2-SO2-T3,其中R2,R3,R4,R5,R6,T1,T'1,T2和T3为 R 1表示选自氢,烷基,芳基,芳基烷基,杂芳基,杂芳基烷基,烷基羰基,芳基羰基,芳基烷基羰基,杂环烷基羰基,烷基磺酰基,芳基磺酰基,芳基烷基磺酰基,膦酰基,芳氧基羰基,烷氧基羰基和 芳基烷氧基羰基,其异构体,以及其与药学上可接受的酸或碱的加成盐。含有该化合物的药物可用于治疗癌症。